Ligand Pharmaceuticals Incorporated (LGND) — Financial statements
Income statement, balance sheet, and cash flow for Ligand Pharmaceuticals Incorporated — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 268↑60.4% | 167↑27.3% | 131↓33.1% | 196↓18.8% | 242 | |
| Cost of Revenue | 7↓40.5% | 11↓68.4% | 35↓33.7% | 53↓15.0% | 62 | |
| Gross Profit | 261↑67.6% | 156↑62.1% | 96↓32.9% | 143↓20.0% | 179 | |
| Operating Expenses | ||||||
| R&D Expenses | 81↑278.9% | 21↓12.7% | 25↓32.0% | 36↑12.4% | 32 | |
| General & Administrative Expenses | 92↑17.5% | 79↑49.0% | 53↓24.7% | 70↑49.7% | 47 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 92↑17.5% | 79↑49.0% | 53↓24.7% | 70↑49.7% | 47 | |
| Other Expenses | 41↓48.2% | 79↑1023.3% | 7↓79.6% | 34↑1113.5% | -3 | |
| Operating Expenses | 214↑19.9% | 179↑111.9% | 84↓39.9% | 140↑85.9% | 76 | |
| Total Costs & Expenses | 221↑16.4% | 190↑58.9% | 119↓38.2% | 193↑40.3% | 138 | |
| Operating Results | ||||||
| Operating Income | 47↑308.8% | -23↓289.3% | 12↑293.2% | 3↓97.1% | 104 | |
| Depreciation & Amortization | 34↓4.2% | 35↓3.5% | 37↓15.8% | 43↓14.8% | 51 | |
| EBITDA | 193↑372.5% | 41↓59.5% | 101↑24.2% | 81↓43.1% | 143 | |
| EBIT | 159↑2761.6% | 6↓91.4% | 64↑70.1% | 38↓58.8% | 92 | |
| Interest & Other Income | ||||||
| Net Interest Income | 9↑78.2% | 5↓28.9% | 7↑2756.3% | 0.25↑101.3% | -19 | |
| Interest Income | 9↑11.0% | 8↑4.5% | 8↑276.9% | 2↑130.9% | 0.89 | |
| Interest Expense | 0.00↓100.0% | 3↑363.0% | 0.66↓63.5% | 2↓90.8% | 20 | |
| Non-Operating Income | -112↓296.9% | -28↑46.2% | -52↓50.6% | -35↓389.1% | 12 | |
| Other Income / Expenses | 112↑344.8% | 25↓51.4% | 52↑56.8% | 33↑204.2% | -32 | |
| Income Before Tax | 159↑6212.9% | 3↓96.0% | 64↑76.8% | 36↓50.1% | 72 | |
| Income Tax Expense | 35↑426.8% | 7↓33.4% | 10↓76.1% | 41↑1094.0% | -4 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 124↑3186.6% | -4↓107.5% | 54↑1131.2% | -5↓106.8% | 76 | |
| Net Income from Discontinued Operations | 0.00 | 0.00↑100.0% | -2↑94.1% | -28↓46.5% | -19 | |
| Net Income | 124↑3186.6% | -4↓107.7% | 52↑256.3% | -33↓158.4% | 57 | |
| Bottom-Line Net Income | 124↑3186.6% | -4↓107.7% | 52↑256.3% | -33↓158.4% | 57 | |
| EPS (Basic) | 6.44↑3027.3% | -0.22↓107.3% | 3.02↑252.5% | -1.98↓157.2% | 3.46 | |
| EPS (Diluted) | 6.13↑2886.4% | -0.22↓107.5% | 2.94↑248.5% | -1.98↓159.3% | 3.34 | |
| Weighted Average Shares | 19↑5.7% | 18↑5.7% | 17↑2.5% | 17↑1.4% | 17 | |
| Weighted Average Diluted Shares | 20↑11.0% | 18↑3.0% | 18↑5.3% | 17↓2.2% | 17 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.